_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
Investment of Rs 235 crores to add 411 beds in the next 18 months
The hospital chain aggressively embarks on digitisation and is e-health ready
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Subscribe To Our Newsletter & Stay Updated
